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Genetic deficiency of angiotensinogen produces an impaired urine
concentrating ability in mice. Angiotensinogen gene-knockout (Atg2/2)
mice lacking angiotensin II exhibit chronic hypotension. The present study
was designed to investigate pathophysiology of Atg2/2 mice from the renal
functional view. Wild-type (Atg1/1) and Atg2/2 mice at 10 weeks of age
were housed in metabolic cages for 24-hour urine collection. When
provided free access to water, Atg2/2 mice showed an increased urine
output and a decreased urine osmolality compared with Atg1/1 mice.
Urinary excretion and plasma levels of vasopressin were significantly
higher in mutant mice than in wild-type mice. On the other hand, urinary
excretion of aldosterone in mutant mice was suppressed to the levels
under the detection limit of the assay system. The mean plasma aldoste-
rone level of Atg2/2 mice was suppressed to 30% of that of Atg1/1 mice.
Plasma levels of creatinine, endogenous creatinine clearance, and urinary
electrolyte excretion were not different between these mice. In Atg1/1
mice, urine osmolality was markedly increased from 1929 6 21 to 3314 6
402 mOsm/kg during water deprivation, whereas this parameter in Atg2/2
mice did not change significantly (from 1413 6 121 to 1590 6 92
mOsm/kg). Urinary vasopressin excretion increased during water depri-
vation from 0.24 6 0.04 and 0.70 6 0.08 to 0.42 6 0.06 and 2.31 6 0.35
ng/mg creatinine in wild-type and mutant mice, respectively. Histologic
study revealed interstitial inflammation, and atrophic changes in the
tubules and papilla in Atg2/2 mice. In conclusion, a genetic deficiency of
angiotensinogen produced an impaired urine concentrating ability and
tubulointerstitial lesions, indicating the critical role of angiotensinogen in
developing normal tubular function and construction.
The renin-angiotensin system (RAS) plays a critical role in
maintaining fluid-electrolyte balance. Angiotensin II regulates
renal tubular functions by modulating sodium/water reabsorption
in the tubules, renal microcirculation, and aldosterone production
in the adrenal glands [1–3]. Pharmacological blockade of angio-
tensin II by angiotensin converting enzyme (ACE) inhibitors or
angiotensin type-1 (AT1) receptor antagonists results in an in-
crease in diuresis and a decrease in urine osmolality [4, 5]. When
administered perinatally, these drugs produce an impaired tubular
function and morphological abnormalities of the renal tissue
[6–9]. However, compensatory effects by the feedback of residual
RAS activity on such metabolic imbalance should be taken into
consideration to assess the results of these pharmacological
studies.
Recent advances in genetic engeneering enabled us to seek a
definitive answer to the physiological role of RAS. We generated
an angiotensinogen gene knockout (Atg2/2) mouse strain by gene
targeting to obtain a model for examining RAS regulation mech-
anisms [10]. Homozygous mutant mice completely lacked angio-
tensinogen and angiotensin peptides, and therefore lacked a
functional RAS. Atg2/2 mice exhibited chronic hypotension,
increased expression of renal renin, and abnormal renal morphol-
ogy [11–14]. Similar abnormalities were reported on another type
of RAS deficient mice that lack the angiotensin converting
enzyme (ACE) gene [15]. On the other hand, angiotensin type-1a
(AT1a) receptor-knockout mice do not show any major his-
topathologic changes in renal tissue, despite that the vascular and
renal effects of angiotensin II are mainly elicited through AT1
receptors [16, 17]. Renal histology of AT2 receptor-deficient mice
was reported to be normal [18]. While functional evidence for the
renal pathophysiology remains to be well understood in these
mutant mice, Esther et al reported that ACE gene-knockout mice
revealed reduced urine concentrating ability and urinary electro-
lyte imbalance [15].
At this time, little is known about how the genetic deficiency of
angiotensinogen affects renal functions and structure in grown
mutant mice. The present study was designed to investigate urine
concentrating ability and endogenous creatinine clearance in
adult Atg2/2 mice. Urinary excretion and plasma levels of vaso-
pressin and aldosterone were also determined, because these
hormones are important regulators for the renal handling of water
and electrolytes.
METHODS
Preparation of experimental animals
Atg2/2 mutant mice were generated by gene targeting as
described previously [10]. The mortality rate of mutant mice
reached 60% during the third postnatal week, whereas that of
wild-type (Atg1/1) mice was less than 1% (Fig. 1). After four
weeks of age, the animals were housed under a 12:12 hour
day:night cycle at a temperature of 25°C with free access to tap
water and a standard laboratory chow. The body weight of Atg2/2
mice at 10 weeks was 10.4% lower (33.5 6 0.7 g) than that of
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Atg1/1 mice (37.4 6 0.4 g, P , 0.05). This delay in weight gain in
mutant mice became evident after nine weeks of the birth. Systolic
blood pressure measured by a tail-cuff method (BP-monitor
MK-1100; Muromachi Kikai Co., Tokyo, Japan) was significantly
lower in mutant mice (69.5 6 2.8 mm Hg) than in wild-type mice
(97.1 6 7.1 mm Hg, P , 0.05). Atg1/1 and Atg2/2 mice at 10
weeks of age were used in the following experiments. Mutant mice
with bilateral severe hydronephrosis were excluded.
Experimental protocols
Mice were kept in metabolic cages for determining daily urine
output, urinary levels of creatinine, osmolality, vasopressin, aldo-
sterone, and electrolytes during a euhydrated condition. Tap
water and standard mouse chow was allowed ad libitum. After
urine collection, blood was obtained from the retro-orbital plexus
with the mice under chloroform anesthesia to determine plasma
creatinine levels. In a separate experiment, mice were decapitated
and plasma vasopressin and aldosterone were determined.
To determine urine concentrating ability, mice were housed in
metabolic cages without access to food. Mineral oil was dropped
on the urine collection chamber to prevent evaporation. Daily
urine output, and urinary levels of creatinine, osmolality, vaso-
pressin, and electrolytes were monitored. In this study, aldoste-
rone was not determined because mineral oil interfered with the
aldosterone assay. During the first 24 hours, mice were provided
free access to water. This control period was followed by the
experimental period of water deprivation for 24 hours. Body
weight was measured before and after the experiment.
In a separate experiment, endogenous creatinine clearance was
determined. Wild-type and mutant mice were divided into control
euhydrated group and dehydrated group, respectively. They were
then housed in metabolic cages and the concentrations of creat-
inine in the plasma and urine samples were determined.
The concentrations of creatinine, osmolality, and electrolytes
were measured by an automated analyzer for routine laboratory
tests (Hitachi-736; Hitachi Co., Tokyo, Japan). Urinary and
plasma concentrations of vasopressin were determined with a
radioimmunoassay kit (AVP-kit Mitsubishi; Mitsubishi Kagaku
Co., Tokyo, Japan) with the detection limit of 0.063 pg/tube. Intra-
and inter-assay variance were less than 7.8% at 1.15 pg/tube and
7.4% at 1.5 pg/tube, respectively. Urinary and plasma concentra-
tions of aldosterone were determined with a radioimmunoassay
kit (SPAC-S aldosterone kit; Daiichi Radio-isotope Co., Tokyo,
Japan). The detection limit of the assay system is 25 pg/ml. Intra-
and inter-assay variance were less than 8.5% and 3.3%, respec-
tively, at 103 pg/ml.
Histologic examination
Kidneys from Atg1/1 and Atg2/2 mice were weighed and
immersion-fixed with 0.1 M phosphate buffer (pH 7.4) containing
4% paraformaldehyde and 0.1% picric acid for four days, and
then embedded in paraffin. Tissue sections of 5 mm were cut and
processed for hematoxylin and eosin staining. Identifiable glomer-
uli were counted in the maximal cross sectional area of the frontal
sections. A total of 20 sections were evaluated from 10 different
animals for each Atg1/1 and Atg2/2 mouse group.
Statistical analysis
Data are expressed as means 6 SE and statistical significance
was determined by unpaired t-test, linear regression analysis or




Table 1 summarizes baseline physiologic parameters from
Atg1/1 and Atg2/2 mice provided with free access to water and
standard mouse chow. Atg2/2 mice showed an increased urine
output and a decreased urine osmolality compared with wild-type
mice. Urinary excretion and plasma levels of vasopressin were 2.9
times and 4.3 times higher in mutant mice than in wild-type mice,
respectively. While detectable levels of aldosterone were found in
the urine samples from Atg1/1 mice, urinary aldosterone levels of
Atg2/2 mice were under the detection limit of the assay system.
Plasma aldosterone levels of mutant mice was significantly lower
than that of wild-type mice. On the other hand, urinary excretions
of sodium, potassium, plasma creatinine levels, and creatinine
clearance were similar in these mice.
Fig. 1. Survival rate of Atg1/1 () and Atg2/2 (l) mice.
Table 1. Baseline data in euhydrated mice
Parameter N Atg1/1 N Atg2/2
UVol ml/g body wt 15 33.1 6 4.4 10 62.2 6 10.0
a
UOsm mOsm/kg 13 2717 6 131 11 1121 6 51
a
UVP/Cr ng/mg 9 0.24 6 0.04 10 0.70 6 0.07
a
UAldo/Cr pg/mg 10 1.97 6 0.27 10 ND
UNa/Cr mEq/mg 18 0.22 6 0.02 16 0.23 6 0.02
UK/Cr mEq/mg 18 0.45 6 0.02 16 0.44 6 0.02
UNa/K 18 0.49 6 0.01 16 0.50 6 0.04
PVP pg/ml 9 2.8 6 0.3 6 12.2 6 3.2
a
PAldo pg/ml 9 410 6 70 6 121 6 21
a
PCr mg/dl 10 0.34 6 0.04 10 0.33 6 0.12
CCr ml/min/g body wt 10 7.28 6 1.50 8 6.42 6 1.51
For 24-hour urine collection, mice were housed in metabolic cages with
free access to standard chow and tap water. Abbreviations are: UVol, urine
volume; UOsm, urine osmolality; UVP/Cr, UAldo/Cr, UNa/Cr, and UK/Cr,
urinary excretion of vasopressin, aldosterone, sodium, and potassium,
respectively, relative to creatinine; ND, not detected; PVP, plasma vaso-
pressin; PAldo, plasma aldosterone; PCr, plasma creatinine; CCr, creatinine
clearance. Values are expressed as means 6 SE.
a P , 0.05 vs. Atg1/1 mice
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Effects of water deprivation
Water deprivation for 24 hours produced a significant reduction
in urine output in both Atg1/1 and Atg2/2 mice. However, the
difference in urine output between wild-type and mutant mice
persisted after the treatment (Fig. 2A). Urine osmolality of
wild-type mice was increased by 72% during water deprivation
period (Fig. 2B), whereas that of mutant mice did not change.
Water deprivation increased the urinary excretion of vasopressin
in both Atg1/1 and Atg2/2 mice. After the treatment, this
parameter of mutant mice was 5.5-times higher than that of
wild-type mice (Fig. 2C). As shown in Figure 3, significant
correlations were observed between urine osmolality and urinary
vasopressin excretion during water deprivation for Atg1/1 mice
(r 5 0.66, P , 0.05) and Atg2/2 mice (r 5 0.78, P , 0.05). When
compared with Atg1/1 mice (slope 5 4798), the mean regression
line of Atg2/2 mice (slope 5 501) showed a shift toward lower
urinary osmolalities for a given urinary vasopressin level. Analysis
of covariance indicated the probability that these slopes were the
same was less than 0.05. During the experimental course, the
Fig. 2. Effects of water deprivation on
parameters related to urine concentrating
ability in Atg1/1 and Atg2/2 mice. Using
metabolic cages, urine volume (UVol), urine
osmolality (UOsm), and urinary excretion of
vasopressin relative to creatinine (UVP/Cr), and
changes in body wt (DBW) were monitored
during a 24-hour control period and following a
water deprivation period (WD). Values are
expressed as means 6 SE from 7 to 12
experiments. *P , 0.05 versus euhydrated wild-
type mice; †P , 0.05 versus dehydrated wild-
type mice; ¶P , 0.05 versus euhydrated mutant
mice. Symbols are: (M) Atg1/1 mice; (o) Atg2/2
mice.
Fig. 3. Relationship between urinary osmolality (UOsm) and urinary
excretion of vasopressin (UVP/Cr) during 24 hours of water deprivation.
Urine osmolality and urinary excretion of vasopressin from individual
Atg1/1 (l) and Atg2/2 () mice are plotted.
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mean body weights were decreased by 25% and 30% for Atg1/1
and Atg2/2 mice, respectively (Fig. 2D).
In euhydrated condition, urinary concentrations of sodium and
potassium were significantly lower in Atg2/2 mice than in Atg1/1
mice (Fig. 4 A, B). In wild-type mice, these parameters were
markedly increased during 24 hours of water deprivation, whereas
they were not affected by the treatment in mutant mice. On the
other hand, the amount of urinary sodium and potassium excre-
tions relative to creatinine did not differ between Atg1/1 and
Atg2/2 mice before and after water deprivation (Fig. 4 C, D).
Urinary sodium to potassium ratio did not change during the
experiment; the ratio before and after water deprivation was
0.675 6 0.064 and 0.769 6 0.075, respectively, for Atg1/1 mice,
and 0.599 6 0.031 and 0.601 6 0.069, respectively, for Atg2/2
mice.
The total creatinine excretion in wild-type mice remained
constant (15.6 6 2.2 and 15.1 6 1.6 mg/g body wt for euhydrated
and dehydrated conditions, respectively), whereas this parameter
in mutant mice was decreased from 17.2 6 1.7 to 9.8 6 1.0 mg/g
body wt (P , 0.05) after the treatment. A separate series of
experiments revealed that the creatinine clearance of Atg1/1 mice
was constant during water deprivation whereas that of Atg2/2
mice was significantly decreased (Fig. 5).
Histologic examination
Figure 6 shows renal sections from Atg1/1 and Atg2/2 mice at
10 weeks of age. Compared with wild-type mice (Fig. 6A), kidneys
from mutant mice exhibited gross morphological abnormalities
such as thinned medulla with papillary atrophy and dilated renal
pelvis (Fig. 6B). In higher magnifications of mutant mice, chronic
interstitial inflammation, tubular atrophy, and wall thickning of
the interlobular arteries and afferent arterioles were observed
(Fig. 6 C, D). The mean glomerular count per maximal cross
sectional area was significantly smaller in Atg2/2 mice (142.5 6
5.3 count/section) than in Atg1/1 mice (178.3 6 7.5 count/section).
Wet kidney weight relative to whole body wt was significantly
Fig. 4. Urinary excretion of sodium and
potassium in Atg1/1 and Atg2/2 mice. Urinary
levels of sodium (UNa) and potassium (UK),
urinary excretion of sodium relative to
creatinine (UNa/Cr), and potassium relative to
creatinine (UK/Cr) were determined during 24-
hour control and water deprivation periods
(WD). Values are expressed as means 6 SE
from 7 to 12 experiments. *P , 0.05 versus
euhydrated wild-type mice; †P , 0.05 versus
dehydrated wild-type mice; ¶P , 0.05 versus
euhydrated mutant mice. Symbols are: (M)
Atg1/1 mice; (o) Atg2/2 mice.
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larger in Atg2/2 mice (1.06 6 0.06 g/g body wt) than in Atg1/1
mice (0.87 6 0.03 g/g body wt, P , 0.05), whereas absolute kidney
weights did not differ between these mice (0.32 6 0.01 and 0.31 6
0.01 g for wild-type and mutant mice, respectively).
DISCUSSION
The important findings of the present study were that Atg2/2
mice showed higher urine output and lower urine osmolality than
Atg1/1 mice. Urine osmolality of wild-type mice was increased by
72% after 24 hours of water deprivation, whereas that of mutant
mice did not change. The difference in urine output persisted
during the water deprivation period. Furthermore, the loss in
body wt during the experiment was larger in mutant mice than in
wild-type mice. These results suggest an absolute impaired urine
concentrating ability in Atg2/2 mice. It could be argued that this
abnormality in mutant mice was the result of a reduced osmotic
sensitivity of the vasopressin secretory mechanism, considering
the stimulatory effect of angiotensin II on the synthesis and
secretion of vasopressin in the hypothalamus [19]. However, the
impaired urine concentrating ability in mutant mice may be due
primarily to a renal cause rather than a central cause, because
urinary vasopressin response to water deprivation was enhanced
in mutant mice. Urinary vasopressin excretion provides an indi-
cation of the total release over the experimental periods such as
water deprivation [20–22]. An increase in urine flow itself cannot
explain the higher amount of urinary vasopressin excretion in
mutant mice, because urinary vasopressin clearance is rather
decreased when urine flow is enhanced with a decrease in urine
concentrating ability [20].
The present study confirms previous evidence for renal mor-
phologic abnormalities such as tubulointerstitial lesions and pap-
illary atrophy in Atg2/2 mice [12]. These regions contain renal
collecting ducts, where vasopressin acts to alter water and urea
permeability. It is therefore reasonable to consider that the
pathologic changes result in the urine concentrating defect in
Atg2/2 mice. Reduced tubular sensitivity to vasopressin may
participate at least partially in this defect. In accord with this view,
an abnormal urine concentrating ability associated with the
tubulointerstitial lesions similarly observed in the present study
was recently demonstrated in another type of RAS-deficient mice
that lack the angiotensin converting enzyme (ACE) gene, al-
though the secretory response of vasopressin to water deprivation
has not been examined [15, 23]. Consistent results have been
reported in rats that had been neonatally treated with ACE
inhibitors [6, 9]. Future studies on pathophysiologic changes in
vasopressin receptor will provide evidence to determine the
mechanism involved in reduced antidiuretic sensitivity of Atg2/2
mice and other RAS-deficient models. Regardless of the mecha-
nism, it is clear that RAS plays a critical role in developing a
normal tubular function as well as a normal tubulointerstitial
construction.
It has been demonstrated that a reduced urine concentrating
ability and tubulointerstitial lesions are generated by the AT1-
selective antagonist losartan administered during an early postna-
tal period, while the AT2-selective antagonist PD 123319 did not
affect nephrogenic process [6–8]. These results suggest that AT1
receptor antagonism is the main cause of the renal functional and
morphologic abnormalities in Atg2/2 mice and other RAS-defi-
cient models. However, controversial results have been reported
on AT1a receptor gene-knockout mice. They did not show major
pathologic changes in the renal tissue [17]. A possible explanation
of this discrepancy is that residual angiotensin type-1b (AT1b)
receptors partially compensate for the defect of AT1a receptor-
mediated signals and prevent the major events occurring during
the nephrogenic process. In our preliminary experiments, AT1a
receptor-knockout mice showed approximately a 1.7-fold larger
urine output and reduced urine osmolality compared with wild-
type mice during 24 hours of water deprivation, thereby suggest-
ing the critical role of AT1a receptor in maintaining urine
concentrating ability (unpublished observations).
Little is known about the role of AT2 receptor in regulating
water handling in the kidney. It has been reported that PD 123319
increases urine output and free water clearance in normal rats
without affecting renal hemodynamics [4, 24]. The results suggest
the direct stimulatory effect of AT2 receptor-mediated signals on
diuresis, while the effect of PD 123319 on water handling under a
dehydrated condition was not examined in these studies. In this
connection, it is noteworthy that wild-type and AT2 receptor
gene-knockout mice show similar losses in body wt during 40
hours of water deprivation, suggesting a normal urine concentrat-
ing ability in AT2 receptor-deficient mice [18].
Effects of angiotensinogen deficiency on tubular morphogene-
sis may be primarily important for the urine concentrating defect
Fig. 5. Effect of water deprivation (WD) on endogenous creatinine
clearance (CCr) in Atg
1/1 and Atg2/2 mice. Wild-type and mutant mice
were divided into euhydrated and dehydrated groups, respectively. Mice
were housed in metabolic cages without access to food. Values are
expressed as means 6 SE from 6 experiments. *P , 0.05 versus euhydrated
wild-type mice; ¶P , 0.05 versus euhydrated mutant mice. Symbols are:
(M) Atg1/1 mice; (o) Atg2/2 mice.
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Fig. 6. Histopathology of the kidneys from 10-week-old Atg1/1 and Atg2/2 mice (hematoxyllin and eosin staining). (A) Renal section from Atg1/1 mice.
(B) Renal section from Atg2/2 mice, showing dilated renal pelvis and papillary atrophy. (C and D) Higher magnification of the sections from mutant
mice, showing an interstitial inflammation (C), tubular atrophy (C), and wall thickening of the interlobular arteries (D). Bars indicate 1 mm (A and B)
and 100 mm (C and D).
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in Atg2/2 mice. Another mechanism by which the genetic defi-
ciency of angiotensinogen could produce an impairment of urine
concentrating ability is an increased renal medullary blood flow.
In normal animals, it is well known that angiotensin II functions as
a vasoconstricting regulator of vasa recta and efferent arteriole of
the juxtamedullary nephrons. This action of angiotensin II de-
creases renal medullary blood flow and increases medullary
interstitial fluid osmolality, thereby raising the urine concentrating
ability [1, 3, 25]. Blockade of angiotensin II generation by
captopril results in concomitant increases in medullary blood flow
and urine volume [22–30]. Therefore, it could be speculated that
complete lack of angiotensin peptides in Atg2/2 mice affect renal
medullary blood flow and that this effect is an additional mecha-
nism involved in the urine concentrating defect in mutant mice.
In the present study, we found significantly lower levels of
urinary and plasma aldosterone in Atg2/2 mice. Okubo et al
recently demonstrated a tendency towards a decrease in plasma
aldosterone in Atg2/2 mice compared with wild-type mice, while
the decrease did not reach statistical significance [31]. Esther et al
also reported the reduced urinary excretion of this hormone in
ACE gene-knockout mice [15]. These results are consistent with
the fact that angiotensin II is a stimulatory regulator for the
synthesis and secretion of aldosterone in the adrenal gland [32,
33]. Aldosterone is one of the most important factors to maintain
sodium/water reabsorption in renal tubules. However, it seems
unlikely that a reduced aldosterone production could account for
the increased urine output in Atg2/2 mice, because the diuresis
due to aldosterone deficiency should be associated with an
increase in sodium excretion. It is possible that there was an
earlier natriuresis and that the Atg2/2 mice were now in a new
state of sodium balance. The lower weight of mutant mice
could be attributed to a chronic state of volume contraction,
which could also account, in part, for the lower blood pressure
levels [14].
Plasma creatinine levels and endogenous creatinine clearance
of Atg2/2 mice were found to be normal in a euhydrated
condition, despite the fact that the mean glomerular number was
reduced in mutant mice. However, creatinine clearance of mutant
mice was significantly decreased after water deprivation. While
precise mechanisms remain to be well understood, volume deple-
tion resulting from the reduced urine concentrating ability com-
bined with severe hypotension could produce a decrease in renal
perfusion pressure to the levels under the range of renal autoreg-
ulation.
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